Sanara MedTech Publishes Economic Value Study on CellerateRX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy SMTI?
Sanara MedTech announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX Surgical Powder in the Journal of Medical Economics. The study estimated the cost-effectiveness of adding CellerateRX as an adjunct to the standard of care for reducing postoperative complications in high-risk spinal surgery patients. The researchers found that the group treated with CellerateRX exhibited a dominant cost-effectiveness profile compared to the group treated with the standard of care alone. Specifically, the CellerateRX treatment arm generated $3,852 in cost savings and a 0.007 QALY gain per patient, yielding a net monetary benefit of $4,542. The primary contributors to cost savings were the avoidance of hospital readmissions and surgical revision procedures, which conservatively accounted for $2,238 and $835 of the total cost reductions, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMTI
Wall Street analysts forecast SMTI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.690
Low
36.00
Averages
36.00
High
36.00
Current: 19.690
Low
36.00
Averages
36.00
High
36.00
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanara MedTech to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Sanara MedTech is set to release its fourth quarter and full year 2025 financial results on March 24, 2026, before U.S. markets open, which is expected to provide critical performance data and future outlook for investors.
- Conference Call Details: The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, likely attracting significant attention from analysts and investors, thereby enhancing market transparency.
- Replay Service Availability: A telephonic replay of the conference call will be available until April 7, 2026, ensuring that investors who cannot participate live can still access the information, thus improving information accessibility.
- Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market aimed at achieving better clinical outcomes and reducing healthcare expenditures, highlighting its strategic importance in the North American surgical tissue repair market.
See More
Sanara MedTech to Present at TD Cowen Health Care Conference
- Conference Participation: Sanara MedTech will participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, with management scheduled to present on March 3 at 9:10 a.m., showcasing the company's innovative technologies in the surgical market.
- Investor Relations: Presentation materials will be posted on the company's investor relations website prior to the event, ensuring timely access to information for investors, thereby enhancing transparency and boosting investor confidence.
- Product Showcase: Sanara MedTech focuses on developing and commercializing surgical products, including CellerateRX® and BIASURGE®, aimed at improving clinical outcomes and reducing healthcare costs, demonstrating the company's competitiveness in the surgical market.
- Market Positioning: The company aims to be an innovative and comprehensive provider of surgical solutions, actively expanding its product line to meet the U.S. market's demand for effective treatments, reflecting its strategic emphasis on future growth.
See More
Sanara MedTech (SMTI) Projects Q4 2025 Revenue of $27.2M to $27.7M
- Revenue Growth Outlook: Sanara MedTech anticipates Q4 2025 net revenue between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5%, indicating stable growth potential in the market.
- BIASURGE Sales Recovery: The company experienced significant sales growth in its BIASURGE Advanced Surgical Solution due to supply chain issues in Q4 2024, with expected net revenue growth of approximately 11% to 13% year-over-year for Q4 2025.
- Annual Financial Guidance: For the full year 2025, net revenue is projected to range from $102.7 million to $103.2 million, representing a year-over-year increase of about 19%, reflecting ongoing growth in the surgical sector and recovering market demand.
- Future Projections: Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating a growth of approximately 13% to 17% compared to the midpoint of the 2025 revenue forecast, showcasing confidence in future growth.
See More
Sanara MedTech Secures Innovative Technology Contract with Vizient for BIASURGE
- Innovative Technology Contract: Sanara MedTech's BIASURGE Advanced Surgical Solution has secured a contract with Vizient, effective January 1, 2026, expanding the company's reach within a healthcare network representing over $156 billion in annual purchasing volume.
- Product Advantages: BIASURGE is a no-rinse irrigation solution designed to cleanse surgical wounds more effectively than saline alone, with its antimicrobial preservative providing broad-spectrum effectiveness that supports infection control strategies and enhances surgical precision.
- Market Potential: The contract was awarded based on recommendations from hospital experts, indicating BIASURGE's unique qualities and potential to improve surgical care, which could significantly enhance the company's market competitiveness and sales.
- Portfolio Expansion: Sanara MedTech also markets CellerateRX Surgical Activated Collagen Powder, FORTIFY tissue repair grafts, and advanced biologic matrices, aimed at improving clinical outcomes while reducing healthcare costs, further solidifying its position in the surgical products market.
See More
Sanara MedTech (SMTI) Announces IPREMIUM Upgrade for BIASURGE Surgical Solution
- Product Upgrade: Sanara MedTech announced that its BIASURGE Advanced Surgical Solution has received an IPREMIUM upgrade, enhancing the product's market competitiveness and expected to improve customer experience.
- Market Impact: This upgrade may attract more healthcare institutions to adopt the solution, potentially driving sales growth in the surgical medical device market and further solidifying the company's market position.
- Technological Innovation: The upgrade of BIASURGE reflects Sanara MedTech's ongoing innovation in surgical technology, aimed at meeting evolving medical needs and enhancing surgical efficiency.
- Strategic Significance: Through this upgrade, Sanara MedTech not only increases the product's added value but also lays the groundwork for future R&D and market expansion, enhancing the company's long-term growth potential.
See More
Investor Notice: Holzer & Holzer, LLC Launches Investigation into Sanara MedTech Inc. (SMTI)
Investigation Announcement: Holzer & Holzer, LLC is investigating Sanara MedTech Inc. for potential violations of federal securities laws following the company's announcement of a strategic realignment and discontinuation of its Tissue Health Plus operations, which led to a drop in stock price.
Investor Outreach: Investors who purchased Sanara stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance regarding their rights.
Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has successfully recovered significant amounts for shareholders affected by corporate misconduct since its establishment in 2000.
Contact Information: Interested parties can reach out to Corey Holzer or Joshua Karr via email or phone for more information about the investigation and potential legal actions.
See More
Sanara MedTech to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Sanara MedTech is set to release its fourth quarter and full year 2025 financial results on March 24, 2026, before U.S. markets open, which is expected to provide critical performance data and future outlook for investors.
- Conference Call Details: The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, likely attracting significant attention from analysts and investors, thereby enhancing market transparency.
- Replay Service Availability: A telephonic replay of the conference call will be available until April 7, 2026, ensuring that investors who cannot participate live can still access the information, thus improving information accessibility.
- Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market aimed at achieving better clinical outcomes and reducing healthcare expenditures, highlighting its strategic importance in the North American surgical tissue repair market.
See More
Sanara MedTech to Present at TD Cowen Health Care Conference
- Conference Participation: Sanara MedTech will participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, with management scheduled to present on March 3 at 9:10 a.m., showcasing the company's innovative technologies in the surgical market.
- Investor Relations: Presentation materials will be posted on the company's investor relations website prior to the event, ensuring timely access to information for investors, thereby enhancing transparency and boosting investor confidence.
- Product Showcase: Sanara MedTech focuses on developing and commercializing surgical products, including CellerateRX® and BIASURGE®, aimed at improving clinical outcomes and reducing healthcare costs, demonstrating the company's competitiveness in the surgical market.
- Market Positioning: The company aims to be an innovative and comprehensive provider of surgical solutions, actively expanding its product line to meet the U.S. market's demand for effective treatments, reflecting its strategic emphasis on future growth.
See More
Sanara MedTech (SMTI) Projects Q4 2025 Revenue of $27.2M to $27.7M
- Revenue Growth Outlook: Sanara MedTech anticipates Q4 2025 net revenue between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5%, indicating stable growth potential in the market.
- BIASURGE Sales Recovery: The company experienced significant sales growth in its BIASURGE Advanced Surgical Solution due to supply chain issues in Q4 2024, with expected net revenue growth of approximately 11% to 13% year-over-year for Q4 2025.
- Annual Financial Guidance: For the full year 2025, net revenue is projected to range from $102.7 million to $103.2 million, representing a year-over-year increase of about 19%, reflecting ongoing growth in the surgical sector and recovering market demand.
- Future Projections: Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating a growth of approximately 13% to 17% compared to the midpoint of the 2025 revenue forecast, showcasing confidence in future growth.
See More
Sanara MedTech Secures Innovative Technology Contract with Vizient for BIASURGE
- Innovative Technology Contract: Sanara MedTech's BIASURGE Advanced Surgical Solution has secured a contract with Vizient, effective January 1, 2026, expanding the company's reach within a healthcare network representing over $156 billion in annual purchasing volume.
- Product Advantages: BIASURGE is a no-rinse irrigation solution designed to cleanse surgical wounds more effectively than saline alone, with its antimicrobial preservative providing broad-spectrum effectiveness that supports infection control strategies and enhances surgical precision.
- Market Potential: The contract was awarded based on recommendations from hospital experts, indicating BIASURGE's unique qualities and potential to improve surgical care, which could significantly enhance the company's market competitiveness and sales.
- Portfolio Expansion: Sanara MedTech also markets CellerateRX Surgical Activated Collagen Powder, FORTIFY tissue repair grafts, and advanced biologic matrices, aimed at improving clinical outcomes while reducing healthcare costs, further solidifying its position in the surgical products market.
See More
Sanara MedTech (SMTI) Announces IPREMIUM Upgrade for BIASURGE Surgical Solution
- Product Upgrade: Sanara MedTech announced that its BIASURGE Advanced Surgical Solution has received an IPREMIUM upgrade, enhancing the product's market competitiveness and expected to improve customer experience.
- Market Impact: This upgrade may attract more healthcare institutions to adopt the solution, potentially driving sales growth in the surgical medical device market and further solidifying the company's market position.
- Technological Innovation: The upgrade of BIASURGE reflects Sanara MedTech's ongoing innovation in surgical technology, aimed at meeting evolving medical needs and enhancing surgical efficiency.
- Strategic Significance: Through this upgrade, Sanara MedTech not only increases the product's added value but also lays the groundwork for future R&D and market expansion, enhancing the company's long-term growth potential.
See More
Investor Notice: Holzer & Holzer, LLC Launches Investigation into Sanara MedTech Inc. (SMTI)
Investigation Announcement: Holzer & Holzer, LLC is investigating Sanara MedTech Inc. for potential violations of federal securities laws following the company's announcement of a strategic realignment and discontinuation of its Tissue Health Plus operations, which led to a drop in stock price.
Investor Outreach: Investors who purchased Sanara stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance regarding their rights.
Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has successfully recovered significant amounts for shareholders affected by corporate misconduct since its establishment in 2000.
Contact Information: Interested parties can reach out to Corey Holzer or Joshua Karr via email or phone for more information about the investigation and potential legal actions.
See More
